Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience
Sponsor: Takeda
Summary
The main aim is to evaluate the relative abuse potential of soticlestat in healthy adults who has used central nervous system (CNS) depressants for recreational nontherapeutic reasons.
Official title: A Phase 1, Randomized, Double-Blind, Double-Dummy, Active- and Placebo-Controlled, 5-Way Crossover Study Evaluating the Abuse Potential of Soticlestat (TAK-935) in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System Depressant Experience
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2022-11-15
Completion Date
2023-07-07
Last Updated
2026-09-16
Healthy Volunteers
Yes
Conditions
Interventions
Soticlestat 300 mg
Administered orally.
Soticlestat 600 mg
Administered orally.
Soticlestat 900 mg
Administered orally.
Alprazolam
Administered orally.
Placebo
Administered orally.
Locations (1)
Altasciences
Overland Park, Kansas, United States